Patent assignee · US · COMPANY

Amplimmune, Inc.

5Patents
5Active
5Granted
50Portfolio score

Filing activity: Aug 25, 2009 → Dec 20, 2011 · 3 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US8609089B2 Compositions of PD-1 antagonists and methods of use Emerging Cross-Sectional Technologies 131 Active
US8709416B2 Compositions of PD-1 antagonists and methods of use Emerging Cross-Sectional Technologies 86 Active
US8114845B2 Compositions of PD-1 antagonists and methods of use Emerging Cross-Sectional Technologies 68 Active
US9005616B2 Methods and compositions for the inhibition of transplant rejection Physics 6 Active
US9011853B2 B7-H4 fusion proteins and methods of use thereof Physics 5 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.